San Antonio

Running trials

• Active, not recruiting

  An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

  NCT02808780· Source

• Active, not recruiting

  A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

  NCT02489318· Phase 3· Source

• Active, not recruiting

  An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

  NCT02531516· Phase 3· Source

• Active, not recruiting

  A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer

  NCT01946204· Phase 3· Source

• Recruiting

  Product Surveillance Registry

  NCT01524276· Source

• Active, not recruiting

  A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

  NCT00606346· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

  NCT02252172· Phase 3· Source

• Completed

  Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer

  NCT02141438· Source

• Completed

  Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

  NCT02073994· Phase 1· Source

• Completed

  A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

  NCT01776840· Phase 3· Source

• Completed

  A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

  NCT01712490· Phase 3· Source